323 326 Y. KITAZAWA ET AL FIG. 3. (a) The chest X-P on the 18th hospital day, revealing severe pulmonary alveolar hemorrhage. (b) The chest X-P on the 23rd hospital day, indicating an improvement in the pulmonary lesion.
often life threatening because of its bleeding tendency. In such cases, measures for hemorrhagic complications are especially important. We present here a young adult case of critical hemophagocytic syndrome (hemophagocytic lymphohistiocytosis [HLH]) after primary EBV infection. After receiving critical care, including hemopurifications and splenectomy, the patient died from multiple organ failure, including fulminant hepatic failure. Specimens from the resected spleen and liver necropsy provided some evidence for the final diagnosis.
THE CASE
The patient was a 23-year-old woman who had not experienced any particular diseases. Her mother had a history of acute myeloid leukemia about 2 years ago. Her uncle had a history of a hemodyscrasia, The Epstein-Barr virus (EBV) is a herpes genus virus that contains DNA of approximately 170 kb as a genome. Most Japanese become infected with EBV during infancy and tend to harbor the infection into adulthood. It is known that the EBV infection may result in various disorders such as infectious mononucleosis, hemophagocytic syndrome, chronic active EBV infection, and lymphoma. Hemophagocytic syndrome may result in anemia, leukocytopenia, and/or thrombocytopenia. Among these cytopenia, thrombocytopenia is Summary: The Epstein-Barr virus (EBV) infection is known to result in infectious mononucleosis, hemophagocytic syndrome, chronic active EBV infection, and lymphoma. Among them, hemophagocytic syndrome sometimes causes thrombocytopenia, which is often life threatening because of its hemorrhagic complications such as gastrointestinal bleeding and pulmonary alveolar hemorrhage. A young adult case of critical hemophagocytic syndrome after primary EBV infection is presented. Chemotherapy was performed using methyl prednisolone succinate, prednisolone, cyclosporin A, and 20 mg/kg of cyclophosphamide. The patient received intensive care, including plasma exchange for hepatic failure, extracorporeal membrane oxygenation for acute respiratory failure, and splenectomy for hemophagocytosis; however, the patient died of multiple organ failure, including fulminant hepatic failure. The pathologic examination of the resected specimen demonstrated infiltrated macrophages containing many phagocytosed erythrocytes. Further immunopathologic examination of these cells showed that the histiocyte markers were positive, whereas the T-cell marker was negative. In view of these findings, definite diagnosis of EBVrelated hemophagocytic lymphohistiocytosis could not be made at that time. The immunohistologic examinations on the liver necropsy specimen provided the evidences suggesting the morbid activation of the hepatic stellate macrophage by EBV-infected T/NK cells and subsequent apoptosis induction of the liver cells through the Fas ligand pathway. Key Words: Fulminant hepatic failure-Plasma exchange-Extracorporeal membrane oxygenation-Splenectomy but the details were unknown. She had symptoms indicating a cold followed by appetite loss and severe general malaise. She consulted her family doctor and was diagnosed as hepatosplenomegaly several days later. She was then referred to Kishiwada City Hospital for further examination. A blood test indicated leukocytopenia, thrombocytopenia, and elevations in hepatic enzymes; therefore, she was admitted to the hospital.
GENERAL CONDITIONS ON ADMISSION
Her height was 167 cm, and her body weight was 61 kg. Her consciousness was clear. Blood pressure was 104/58 mm Hg. Her body temperature was 40.5°C, and her respiratory rate was 18 breaths per minute. The bulbar conjunctiva was icteric but not anemic. She had swollen cervical lymph nodes, and her pharynx was reddish. Abdominal examinations revealed hepatosplenomegaly and a small quantity of ascites. The petechiae on the extremities were observed.
CLINICAL COURSE IN THE HOSPITAL
The patient's blood test results on admission are presented ( Table 1 ). She had leukocytopenia of 1850 per μL and thrombocytopenia of 4.4 × 10 4 per μL. According to the coagulation system tests, fibrin/fibrinogen-degenerated products-D-dimer was elevated to 23.4 μg/mL, whereas the prothrombin time was within the normal range. Subsequent laboratory test results were as follows: hepatic dysfunction, including aspartate aminotransferase (AST) of 603 U/L, alanine aminotransferase (ALT) of 291 U/L, total bilirubin of 3.7 mg/dL, and direct bilirubin of 2.8 mg/dL. In addition, the concentration of ferritin was elevated to 488 ng/mL (the maximal data of 62,490 ng/mL were recorded on the 14th hospital day). This suggested that a lymphoproliferative disorder, such as HLH or malignant lymphoma, had been triggered by some viral infection. The immunological viral tests for EBV could not prove whether the patient was in early stage of infection or whether she simply had a history of old EBV infection ( Table 2 ). From the data of viral antibody titers, the cause was not clear. Administrations of corticosteroid and γ-globulin were started at once, and a bone marrow examination was performed on the second hospital day. The nuclear cell count was 10.4 × 10 4 per μL, and atypical cells were not found. Although macrophage count was 2.8% of the nuclear cell count, there were some macrophages with hemophagocytosis as shown ( Fig. 1 ). Megakaryocyte count was 60 per μL. These data were within the Henter's diagnostic criteria for HLH (1); hence, we diagnosed it as secondary HLH. In order to rule out the primary/familyrelated HLH (FLH), a chromosomal examination was performed. Although a chromosomal aberration of 46XX inv(11)(p11.2q13) was found ( Fig. 2) , there were no FLH-related anomalies, such as aberrations on perforin genes. After starting the medical treatment, white blood cells, platelet count, and LDH showed temporary ameliorations, followed by re-exacerbations. In addition to the aggravation of laboratory test data, hemorrhagic symptoms such as epistaxis appeared on the eighth hospital day. Corticosteroid pulse therapy was started using 1 g/d of methyl prednisolone succinate for 3 days but failed to ameliorate; therefore, further intensive care was required, and the patient was transferred to the intensive care unit on the 10th hospital day.
At the intensive care unit, all of the blood test data, such as blood cell count, hemocoagulability, and hepatic enzyme levels, were abnormal. The results were as follows: white blood cells, 1220 per μL; Hb, 10.7 g/dL; platelet count, 3.7 × 10 4 per μL; prothrombin, 37.3%; fibrin/fibrinogendegenerated products-D-dimer, 9.8 μg/dL; AST, 1250 U/L; ALT, 818 U/L; lactose dehydrogenase (LDH), 2627 U/L; total bilirubin, 7.4 mg/dL; direct bilirubin, 5.9 mg/dL; and C-reactive protein, 1.01 mg/dL. The extreme elevation in hepatic enzyme levels suggested acute serious hepatitis. According to the results of virus antibody titers, it was speculated that the diagnosis might be HLH caused by EBV. The administration of γ-globulin in high dose was introduced, expecting the beneficial effects against viral-infected cells. In order to modulate cytokines derived from infected cells and to suppress the phagocytic activity of macrophage, steroid pulse therapy using 2 g/d of methyl prednisolone succinate for 3 days was introduced, followed by the maintenance therapy using 60 mg/d of prednisolone, 3 mg/kg of cyclosporin A (CsA), and 20 mg/kg of cyclophosphamide as immunological chemotherapies. In order to reduce hypercytokinemia and to support liver failure, plasma exchange was performed. Blood transfusion and the administration of granulocyte-colony stimulating factor were performed for the cytopenia. The activity of hemophagocytosis was monitored and assessed by serum AST, LDH, and ferritin as markers. The episode of pulmonary alveolar hemorrhage that developed on the 18th hospital day resulted in severe respiratory failure (Fig. 3 ). Because the PaO 2 /FiO 2 ratio fell below 40 afterward, the extracorporeal membrane oxygenation was introduced on the 20th hospital day (2) . The pulmonary function gradually improved, and the extracorporeal membrane oxygenation therapy was weaned on the 23rd hospital day. General condition improved, and blood test results showed marked improvement. Splenectomy was performed on the 25th hospital day to reduce hemophagocytosis. The pathologic examination of the resected specimen demonstrated infiltrated macrophages containing many phagocytosed erythrocytes. Further immunopathologic examination of these cells showed that the histiocyte markers of CD68 and leucocyte common antigen were positive, whereas the T-cell and B-cell markers of UCHL-1 and L-26 were negative. In addition, there was no lymphoid atypism, and CD30 was negative. Histiocyte-rich lymphoma was excluded from the diagnosis. In view of the T-cell marker being negative, definite diagnosis of EBV-related HLH was not made, and the present treatment was continued. Even though the various blood purification therapies, including continuous hemodiafiltration and bilirubin absorption, were performed, the patient died on the 39th hospital day without responding to these treatments. The pathologic examination of the liver necropsy tissue demonstrated a massive centric lobular necrosis and showed an acute atrophic hepatitis, so-called red atrophy of the liver (Fig. 4) . It also showed a severe infiltration of the T cell with a large size and a nuclear atypia appearance to the liver. Further immunohistologic examinations on these permeated cells, using UCHL-1 as a marker of T-cell system was positive, and CD8 as a marker of T/NK cell was also positive (Fig. 5a ). The examination of the mononuclear phagocyte system using flow cytometry demonstrated that there was no evidence for monoclonal cell growth in those infiltrated T cells and that the malignant transformation was excluded. In addition, with further examination using in situ hybridization method, there were innumerable apoptosis positive cells in the liver. Tests also confirmed the manifestations of Fas ligand on the stellate macrophage and Fas receptors on the liver cells at the same time. Further examination showed that these infiltrated T cells were infected by EBV using immunohistochemical staining with EBV-LMP1 and EBV-EBNA2. The EBV-LMP1-positive cells (EBV-positive cells) were present (Fig. 5b ). They were also confirmed to be CD8-positive cells. In the spleen, there were also infiltrated lymphocytes and EBV-LMP1-positive and CD8-positive T/NK cells. These evidences suggest the morbid activation of the hepatic stellate macrophage by EBV-infected T/NK cells and subsequent apoptosis induction of the liver cells through the Fas ligand pathway. The evidence suggests that EBV caused the HLH. (3) reported an HLH case in 1939. After Risdall et al (4) reported that some viruses may cause HLH in 1979, various studies have been published to date. As the etiology and pathogenic mechanism is being elucidated, the classification of HLH is still unsettled. Recently, HLH has been classified into primary/hereditary and secondary/ reactive types. Because the patient had some close relationships, it is very likely that this case falls under secondary HLH. Although the chromosomal aberration found in this case has not been reported in FLH cases, similar chromosomal findings might be proved with FLH in the future.
DISCUSSION
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Among the secondary/reactive type, the infection type was diagnosed in this case. It is reported that survival of 60% to 70% is expected based only on basic therapy and supportive care for the general condition as for infection-related HLH except for the EBV-related variety (5, 6) . Because EBV-related HLH often falls into a critical state, a strong immunochemotherapy should be chosen for such cases, as well as intensive care. In addition, a delay in initial treatment may lead to serious consequences; however, the evidence for EBV infection was not indicated in this case because EBV antibody titers were at low levels and lymphoid staining could not detect T cells in the splenic tissue. It is known that with a high soluble interleukin-2 receptor level (23,100 U/mL in this case), one often falls into a critical condition.
Although EBV usually infects B lymphocytes and results in cryptogenic infection, it sometimes infects T lymphocytes and results in a serious condition. Infectious mononucleosis caused by EBV or cytomegalovirus could be recognized in early hospital days. Viral examinations for EBV provided that the pattern, which is generally assessable as an old infection. A cytomegalovirus infection was excluded because of negative C7-HRP. It was assumed that in this case, the patient was recognized to have HLH caused by an infection by some viruses or bacteria in early hospital days. Nevertheless, this case had HLH with extensive hepatic dysfunction and severe cytopenia, and EBV infection should have been considered much earlier and the lymph nodal specimen or peripheral lymphocytes investigated.
It is usual to administer steroid and γ-globulin for infection-related HLH (except for EBV-HLH), and CsA should be administered for aggravated cases. Etoposide (VP-16) is one of the main chemotherapy agents for EBV-HLH, and its administration is for the examination of macrophage and abnormally activated T lymphocyte (7) . It has been reported that early administration of VP-16 improves convalescence in patients with EBV-HLH (8) . As a result, in this case, we were not able to save her life with standard therapy for HLH. From the change in serum ferritin level, the immunosuppressive effect might be insufficient in the early days in the hospital. In cases of hereditary HLH and tumor-related HLH and EBV-HLH, the therapeutic strategy should be planned mainly on the strong immunosuppressive therapy using VP-16, if we can predict the necessity of hematopoietic stem cell transplantation because of extensive cytopenia and hepatic dysfunction. It remains controversial whether splenectomy is effective for HLH. Splenectomy was performed in this case, resulting in an immediate increase in red blood cells, white blood cells, and platelet count. The platelet transfusion was therefore stopped. The changes in phagocytosis activity suggest that this therapy cannot suppress the macrophage activity.
The difficulty in precise control of serum concentration of CsA also may be one cause of the problem. The HLH-94 protocol (9,10) mentioned that the appropriate trough level of CsA was 200 mg/L. In this case, blood CsA level reached 327 mg/L, which was within the effective range.
CONCLUSION
It is necessary to keep in mind that intensive immunosuppression, beside the intensive care for organ supports, should be the basic strategy for the treatment of EBV-HLH.
